Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Kidney Int. 2013 Nov 6;85(5):1225–1237. doi: 10.1038/ki.2013.422

Table 1.

Clinical characteristics of patients with glomerular disease in this study.

Case #1 Case #2 Case #3
Age 41 73 69
Gender Female Male Male
Renal pathology Membranous nephropathy Membranoproliferative glomerulonephritis (IgG3 isotype) Membranous nephropathy
Proteinuria 4.7g/24 hours 4.6g/24 hours 1.8g/24 hours
Serum Creatinine 0.6mg/dL 2.5mg/dL 1.2mg/dL
eGFR >60ml/min 42ml/min/SA¥ 60ml/min
Treatment Losartan 100mg/d
Furosemide 40mg /d		 CyBorD protocol* cycle 1
Amlodipine 5mg/d
Bumetanide 0.5 mg qod
Metoprolol succinate 25 mg/d
Lisinopril/HCTZ 30–37.5 mg /d		 Lisinopril 40mg/d
Metoprolol succinate 25 mg/d
Proteins identified 3258 3197 4189
*

CyBorD protocol: 150 mg/m2 of cyclophosphamide po once weekly(dose reduced for renal function and age), 20 mg of dexamethasone po once weekly, 3 mg (1.5 mg/m2) of subcutaneous bortezomib once weekly. Each cycle consisted of four treatments, usually 3–6 cycles.

¥

Measured by 24 hour urine creatinine clearance.